uniQure shares are trading higher after the company announced it scheduled a Type A meeting with the FDA to discuss the Biologics License Application data package to support accelerated approval of AMT-130.

uniQure N.V. -14.00%

uniQure N.V.

QURE

9.03

-14.00%

uniQure shares are trading higher after the company announced it scheduled a Type A meeting with the FDA to discuss the Biologics License Application data package to support accelerated approval of AMT-130.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via